Clinical trials: Psychological Disorders
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Schizophrenia
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
- Trial name
- NCT05110157
- Testing
- Valbenazine
- Where
- 87 sites in United States, Argentina and 2 more
- Volunteers
- 442 people
- Sponsor
- Neurocrine Biosciences
Mild Cognitive Impairment
Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment
This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment…
- Trial name
- INHANCE-MCI (NCT07243600)
- Testing
- Computerized speed-based cognitive training, Computerized executive function cognitive training
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Posit Science Corporation
Alzheimer's Disease
A Safety and Tolerability Study of ABT-126 in Elderly
The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.
- Trial name
- NCT00867399
- Testing
- ABT-126
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abbott
Narcolepsy, Sleep Apnea, Obstructive
Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness…
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Trial name
- NCT00078312
- Testing
- CEP-10953 (Armodafinil)
- Where
- 50 sites in United States, Russia
- Volunteers
- 328 people
- Sponsor
- Cephalon
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Retinal Metabolic Imaging of Alzheimer Patient
This research project concerns the evaluation of the Metabolic Hyperspectral Retinal Camera (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid plaques, a hallmark of Alzheimer's disease…
- Trial name
- NCT03420807
- Testing
- MHRC
- Where
- Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Mental Health Conditions, Allergic
Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study
This study explores how help-seeking behaviors for both emotional well-being and allergies impact the management of allergic rhinitis, asthma, and mental health symptoms, including anxiety and depression.
- Trial name
- NCT06623799
- Where
- United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- QHSLab, Inc.
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Low Mood
Effect of a Nutritional Supplement on Mental Wellness in Adults
Trillions of microbes reside in human gut and constitute "gut microbiota". Composition of these microbes and substances produced by them play an important role in human health and wellness.
- Trial name
- NCT06058364
- Testing
- Intervention 1 - Triglyceride
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pharmavite LLC
Schizophrenia
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
Various studies suggest that patients treated with Olanzapine can experience a substantial weight gain, while no changes have been observed in patients treated with Ziprasidone.
- Trial name
- NCT00239109
- Testing
- Ziprasidone, Olanzapine, Scales
- Where
- 7 sites in Spain
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Alcohol Use Disorder
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
This study is aimed at examining whether GET73 modulates the indices of central glutamate and γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use Disorder (AUD) criteria, as measured by proton…
- Trial name
- NCT03418623
- Testing
- GET73
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
The purpose of the study is to explore the maintained efficacy, tolerability, and safety of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00757705
- Testing
- Paliperidone ER
- Volunteers
- 299 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
This is a single-centre research study in patients seen within an NHS Improving Access to Psychological Interventions (IAPT) service with suspected generalised anxiety disorder (GAD).
- Trial name
- NCT02901080
- Testing
- Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire
- Where
- United Kingdom
- Volunteers
- 161 people
- Sponsor
- Electromedical Products International, Inc.
Insomnia Disorders
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document…
- Trial name
- NCT03375203
- Testing
- JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg
- Where
- 56 sites in United States, Belgium and 4 more
- Volunteers
- 365 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients…
- Trial name
- NCT00415142
- Testing
- saredutant (SR48968), escitalopram
- Where
- 8 sites in United States, Croatia and 6 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Anxiety
Breathwork Training Reduces Anxiety In Outpatient Gastrointestinal Procedures
Preoperative anxiety is common in outpatient procedures and can negatively impact physiologic stability and recovery. Non-pharmacologic interventions may offer a safe alternative to traditional anxiolytics.
- Trial name
- NCT07647341
- Testing
- paced breathwork
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Calm and Sense Technologies LLC
Alzheimer's Disease
A Safety Study of LY2886721 Single Doses in Healthy Subjects
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.
- Trial name
- NCT01133405
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.